IDEXX Laboratories Inc. outlined its innovation-driven growth strategy at the Raymond James 47th Annual Institutional Investors Conference, highlighting a global veterinary testing opportunity tied to a 45 billion dollar-plus total addressable market in veterinary medical services. The company emphasized new point-of-care platforms and expansion into disease areas including oncology, along with leveraging its installed base through menu extensions, vertical SaaS and AI enablement, and increased international commercial reach. IDEXX also discussed the IDEXX Cancer Dx platform, including performance metrics for canine lymphoma and mast cell tumors, and described plans to broaden cancer screening as part of preventive care panels for at-risk dogs. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEXX Laboratories Inc. published the original content used to generate this news brief on March 02, 2026, and is solely responsible for the information contained therein.